Alleged failures to follow regulations by US pharma company Orexigen Therapeutics (Nasdaq: OREX) in its trial of obesity drug Contrave must not “become a trend,” former US Food and Drug Administration deputy commissioner Joshua Sharfstein told The Pharma Letter.
He has expressed his disappointment with the actions of Orexigen in publishing early and “misleading” trial data public about Contrave (naltrexone HCl/bupropion HCl) and whether it has a cardiovascular benefit.
The company calls Contrave the USA’s leading branded prescription treatment option for certain overweight and obese adults for chronic weight management.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze